Insulin Delivery Devices Market - Forecasts From 2018 to 2023

  • ID: 4718369
  • Report
  • 107 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4


  • Biocon Limited
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Insulet Corporation
  • Medtronic
  • Novo Nordisk
  • MORE
The global Insulin Delivery Devices market is expected to reach US$15.593 billion by 2023 from US$10.370 billion in 2017 growing at a CAGR of 7.03%. Insulin Delivery Devices are used to administer insulin to the diabetic patients. There are many different types of insulin delivery devices available including syringes, pens, jet injectors, oral insulin and pumps etc. giving patients number of options to decide as per their ease and convenience. Alternate forms of insulin delivery are being developed to overcome problems with current subcutaneous insulin injection therapy like poor compliance due to pain, variable absorption lack of feedback control. Insulin Delivery Devices market will show robust growth during the forecast period owing to the rising prevalence of the diabetes because of sedentary life style and rising number of geriatric population across the globe. Continuous technological innovations and advancements in insulin delivery devices for increasing patient compliance will also boost the adoption of the Insulin Delivery Devices during the given forecast period. Poor reimbursement structure and insurance coverage in developing countries might restrain the growth of the Insulin Delivery Devices market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Insulin Delivery Devices market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Insulin Delivery Devices market.

Major industry players profiled as part of the report are Medtronic, Sanofi and Novo Nordisk among others.


By Types

Insulin Pens
Insulin Pumps

By Application

Type I Diabetes
Type II Diabetes
Gestational Diabetes

By End Users

Hospitals and Clinics
Ambulatory Care Settings
Home Care Settings

By Geography

North America
United States

South America

United Kingdom

Middle East and Africa
Saudi Arabia

Asia Pacific
South Korea
Note: Product cover images may vary from those shown
2 of 4


  • Biocon Limited
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Insulet Corporation
  • Medtronic
  • Novo Nordisk
  • MORE
1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. Key Findings of the Study

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis

5. Insulin Delivery Devices Market Forecast by Type
5.1. Insulin Pens
5.2. Syringes
5.3. Insulin Pumps
5.4. Inhalers
5.5. Others

6. Insulin Delivery Devices Market Forecast by Application
6.1. Type I Diabetes
6.2. Type II Diabetes
6.3. Gestational Diabetes

7. Insulin Delivery Devices Market Forecast by End Users
7.1. Hospitals and Clinics
7.2. Ambulatory Care Settings
7.3. Home Care Settings

8. Insulin Delivery Devices Market Forecast by Geography
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others

9. Competitive intelligence
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals

10. Company Profiles
10.1. Novo Nordisk
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Becton, Dickinson and Company
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Medtronic
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Sanofi
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. ELI Lilly and Company
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Ypsomed AG
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Biocon Limited
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Insulet Corporation
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Tandem Diabetes Care, Inc.
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. F. Hoffmann-La Roche Ltd
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Novo Nordisk
  • Becton, Dickinson and Company
  • Medtronic
  • Sanofi
  • ELI Lilly and Company
  • Ypsomed AG
  • Biocon Limited
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • F. Hoffmann-La Roche Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown